GSK's Respiratory Syncytial Virus Vaccine Given Together With Shingles Shot Shows Non-Inferior Immune Response In Older Adults
GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of Arexvy (Respiratory Syncytial Virus Vaccine) when co-administered with Shingrix (Zoster Vaccine).
GSK Reports Findings on Coadministered RSV and Shingles Vaccines
Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.
Good signs for co administration of GSK’s RSV and shingles vaccines
UK drugmaker GSK presented positive Phase III trial data at the European Geriatric Medicine Society Congress. The trial showed that co-administering Arexvy (RSV vaccine) and Shingrix (shingles vaccine) in adults 50+ produced a non-inferior immune response and was well tolerated.
GSK shingles vaccine now available in Malaysia
GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced the launch of its Herpes Zoster vaccine, Shingrix (MAL24056002ARZ), also known as Recombinant Zoster Vaccine, Adjuvanted (RZV) in Malaysia for the prevention of shingles (herpes zoster,
GSK's RSV, Shingles vaccines show on-par immune response in joint trial
(Reuters) -British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot together generated the same immune response in a late-stage trial as separate adminstration of the vaccines.
GSK Sees Positive Results in Trial of Combination RSV, Shingles Vaccine
GSK recorded positive topline data in a late stage trial of its respiratory syncytial virus vaccine combined with a shingles vaccine in treating adults 50 years and older. The British pharma giant said Wednesday a Phase 3 study evaluating RSV vaccine Arexvy co-administered with Shingrix met the primary endpoint,
GSK Reports Positive Data From Co-administration Of RSV And Shingles Vaccines
GSK plc (GSK, GSK.L) announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the
GSK's RSV vaccine meets main goal when co-administered with shingles shot
British drugmaker GSK said on Wednesday its respiratory syncytial virus (RSV) vaccine, when given together with its shingles shot, met the main goal of a late-stage trial in adults over 50 years of age.
Armed robbery in Revesby15h
More Australians to Get Funded Shingles Vaccine
Melbourne, Australia The Government has expanded access to GSK's shingles vaccine, Shingrix, to cover individuals aged 18 ...
dermatologyadvisor9d
No Increased Risk for Incident Gout After RZV Exposure Among Adults Aged 50 Years or Older
The risk for incident gout following RZV exposure was not increased among adults aged 50 years or older, according to study findings.
More Australians will be able to get a free vaccine for shingles
About one in three people will develop shingles in their lifetime and nearly all adults aged 50 years and older carry the inactive virus that causes it. But the the risk of develo ...
Joplin Globe4d
GSK Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX
Please see full Prescribing Information for AREXVY. About SHINGRIX (Recombinant Zoster Vaccine or RZV) SHINGRIX is a non-live, recombinant subunit vaccine indicated for the prevention of ...
Medscape4d
Varicella and Varicella-Zoster Vaccine
The Advisory Committee on Immunization Practices (ACIP) recommends a single dose of zoster vaccine for immunocompetent adults 60 years of age and older, based on the results of this study ...
clinicaladvisor.com13d
Shingles Vaccine May Lower Dementia Risk, Increases Diagnosis-Free Time
Researchers conducted an observational study to compare the risk for dementia associated with both the live and recombinant shingles vaccines.
Renal & Urology News9d
No Increased Risk for Incident Gout After RZV Exposure Among Adults Aged 50+
Among the 461,323 individuals who received at least 1 RZV dose, 1264 experienced new-onset gout within 60 days postvaccination; 302 patients were determined to have incident cases of gout, with no ...
More Australians to get free vaccine for shingles
Australians ages 18 to 64 who are classed as "moderate to high risk" will be able to get the shingles jab. ...
bernama5d
Shingles May Cause Long-Term Pain In Older People – Expert
PHN is characterised by pain lasting from three months to several years after the rash subsides, and it is also the most ...